A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Preoperative Brigatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Fusions.
Clinical trial NCT05361564 · UNKNOWN
Trial details
- NCT number
- NCT05361564
- Sponsor
- Yonsei University
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-06-01
- Primary completion
- 2024-06-01
- Enrollment
- 12
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.